Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cystic fibrosis study targets hidden bacterial threat

NCT ID NCT06371261

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de la Réunion Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how different types of Achromobacter bacteria affect the lungs of people with cystic fibrosis on Réunion Island. Researchers will analyze sputum samples from 17 patients to see if certain species cause more lung infections or lead to worse outcomes. The goal is to better understand which bacteria are most harmful, so doctors can improve treatment and prevent the spread of dangerous strains.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which Achromobacter species are most dangerous, leading to better infection control and treatment strategies for cystic fibrosis patients.
What could go wrong
This is a small, observational study with only 17 participants, so findings may not apply to all patients. It does not test a new treatment, so direct patient benefit is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

17 people

The number who actually took part.

Started

Mar 2024

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cohort of cystic fibrosis patients from Reunion island with Achromobacter spp colonisation

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Minor or major cystic fibrosis patients * Patients with at least one sputum cytobacteriological test positive for Achromobacter spp. during the inclusion period. * Patients living in La Réunion island. * Patients for whom a non-opposition was obtained orally (if applicable from both one of the child's legal guardians and the child him/herself) Exclusion Criteria: * Patients without cystic fibrosis. * Patients with cystic fibrosis but no Achromobacter-positive ECBC during the study inclusion period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cystic fibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cystic fibrosis

Contacts and locations

Locations

  • CHU la Réunion North

    Saint-Denis, Reunion

  • CHU la Réunion South

    Saint-Pierre, Reunion

More trials for these conditions

Other studies related to the condition(s) this trial covers.